Neo Ivy Capital Management Makes New Investment in Boston Scientific Corporation $BSX

Neo Ivy Capital Management purchased a new stake in Boston Scientific Corporation (NYSE:BSX) in the 2nd quarter, HoldingsChannel.com reports. The institutional investor purchased 7,392 shares of the medical equipment provider’s stock, valued at approximately $794,000.

A number of other hedge funds and other institutional investors have also made changes to their positions in BSX. Riverwater Partners LLC lifted its holdings in Boston Scientific by 3.3% in the second quarter. Riverwater Partners LLC now owns 3,104 shares of the medical equipment provider’s stock valued at $333,000 after acquiring an additional 98 shares during the last quarter. IVC Wealth Advisors LLC raised its position in Boston Scientific by 4.9% in the second quarter. IVC Wealth Advisors LLC now owns 2,199 shares of the medical equipment provider’s stock valued at $236,000 after purchasing an additional 102 shares during the period. HHM Wealth Advisors LLC raised its position in Boston Scientific by 13.2% in the first quarter. HHM Wealth Advisors LLC now owns 881 shares of the medical equipment provider’s stock valued at $89,000 after purchasing an additional 103 shares during the period. Rise Advisors LLC grew its holdings in shares of Boston Scientific by 13.9% during the 1st quarter. Rise Advisors LLC now owns 844 shares of the medical equipment provider’s stock worth $85,000 after purchasing an additional 103 shares during the period. Finally, Sound View Wealth Advisors Group LLC grew its holdings in shares of Boston Scientific by 3.9% during the 2nd quarter. Sound View Wealth Advisors Group LLC now owns 2,738 shares of the medical equipment provider’s stock worth $294,000 after purchasing an additional 103 shares during the period. Institutional investors and hedge funds own 89.07% of the company’s stock.

Insider Activity

In related news, Director Ellen M. Zane sold 12,891 shares of the stock in a transaction on Thursday, November 6th. The shares were sold at an average price of $98.28, for a total transaction of $1,266,927.48. Following the completion of the sale, the director owned 24,134 shares in the company, valued at $2,371,889.52. This represents a 34.82% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, EVP Joseph Michael Fitzgerald sold 50,000 shares of Boston Scientific stock in a transaction on Wednesday, October 1st. The shares were sold at an average price of $98.47, for a total transaction of $4,923,500.00. Following the completion of the transaction, the executive vice president owned 178,342 shares in the company, valued at approximately $17,561,336.74. This represents a 21.90% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. In the last ninety days, insiders have sold 175,782 shares of company stock worth $17,742,314. Corporate insiders own 0.50% of the company’s stock.

Analysts Set New Price Targets

A number of research analysts have commented on the stock. Robert W. Baird upped their target price on shares of Boston Scientific from $123.00 to $128.00 and gave the company an “outperform” rating in a research report on Wednesday, October 1st. Needham & Company LLC reissued a “buy” rating and issued a $121.00 price target on shares of Boston Scientific in a research note on Friday, October 17th. Oppenheimer raised shares of Boston Scientific from a “market perform” rating to an “outperform” rating and increased their price objective for the stock from $118.00 to $125.00 in a research report on Monday, September 8th. BTIG Research reissued a “buy” rating and issued a $132.00 target price on shares of Boston Scientific in a research report on Friday. Finally, Wall Street Zen upgraded Boston Scientific from a “hold” rating to a “buy” rating in a research report on Saturday, October 11th. Two research analysts have rated the stock with a Strong Buy rating, twenty-one have issued a Buy rating and two have given a Hold rating to the company’s stock. According to MarketBeat.com, the company has a consensus rating of “Buy” and a consensus price target of $123.77.

Boston Scientific Price Performance

BSX stock opened at $96.77 on Friday. The stock has a market cap of $143.46 billion, a price-to-earnings ratio of 51.75, a PEG ratio of 2.02 and a beta of 0.58. The company has a quick ratio of 0.82, a current ratio of 1.37 and a debt-to-equity ratio of 0.49. Boston Scientific Corporation has a fifty-two week low of $85.98 and a fifty-two week high of $109.50. The business has a 50 day moving average price of $98.97 and a 200 day moving average price of $102.38.

Boston Scientific (NYSE:BSX) last posted its earnings results on Wednesday, October 22nd. The medical equipment provider reported $0.75 EPS for the quarter, beating analysts’ consensus estimates of $0.71 by $0.04. Boston Scientific had a net margin of 14.43% and a return on equity of 19.74%. The firm had revenue of $5.07 billion for the quarter, compared to the consensus estimate of $4.97 billion. During the same period last year, the firm posted $0.63 EPS. The company’s revenue was up 20.3% on a year-over-year basis. Boston Scientific has set its FY 2025 guidance at 3.020-3.040 EPS. Q4 2025 guidance at 0.770-0.790 EPS. Equities research analysts anticipate that Boston Scientific Corporation will post 2.85 earnings per share for the current fiscal year.

Boston Scientific Company Profile

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through two segments, MedSurg and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, direct visualization systems, digital catheters, and single-use duodenoscopes; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, artificial urinary sphincter, laser system, fiber, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator system, proprietary programming software, radiofrequency generator, indirect decompression systems, practice optimization tools, and deep brain stimulation system.